Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II

European Journal of Ophthalmology

Volumn 22, Issue 5, 2012, Pages 687-694

  Autrata, Rudolf ^a   Krejčířová, Inka ^a   Šenková, Kateřina ^a   Holoušová, Marie ^a   Doležel, Zdeněk ^a   Borek, Ivo ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Anti VEGF; Pegaptanib (Macugen); RetCam photography; Retinopathy of prematurity; Stage 3+; Zone I

Indexed keywords

PEGAPTANIB;

ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CRYOTHERAPY; DIODE LASER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFANT; LASER COAGULATION; MALE; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA;

ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; CRYOTHERAPY; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; LASER COAGULATION; LASERS, SEMICONDUCTOR; MALE; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864922801     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000166     Document Type: Article

References (24)

1. Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336: 1221-3.
2. Giannantonio C, Papacci P, Molle F, Lepore D, Gallini F, Romagnoli C. An epidemiological analysis of retinopathy of prematurity over 10 years. J Pediatr Ophthalmol Strabismus 2008; 45: 162-7.
3. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84: 77-82.
4. Katz X, Kychenthal A, Dorta P. Zone I retinopathy of prematurity. J AAPOS 2000; 4: 373-6.
5. O'Keefe M, Lanigan B, Long VW. Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand 2003; 81: 614-6.
6. Recsan Z, Vamos R, Salacz G. Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2003; 40: 204-7.
7. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 2006; 26 (suppl): S11-5.
8. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-9.
9. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-94.
10. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Arch Ophthalmol 1990; 108: 195-204.
11. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007; 10: 133-40.
12. Smith LEH. Through the eyes of a child: understanding retinopathy through ROP: The Friedenwald Lecture. Invest Ophthalmol Vis Sci 2008; 49: 5177-82.
13. Flynn JT, Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 2006; 142: 46-59.
14. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab Invest 1996; 74: 68-77.
15. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009; 21: 182-7.
16. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1727-30.
17. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007; 38: 233-7.
18. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92: 1450-5.
19. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061-3.
20. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II [erratum 2008; 28: 1374]. Retina 2008; 28: 831-8.
21. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28 (suppl): S19-25.
22. Lee JY, Chae JB, Yang SJ, Yoon YH, Kim J-G. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1257-62.
23. Roohipoor R, Ghassemi H, Ghassemi F, et al. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol 2011; 2489: 1295-301.
24. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-15.